June 30, 2020 / 12:31 PM / in 15 days

BRIEF-Oncternal Therapeutics Announces Orphan Drug Designations Of Cirmtuzumab Antibody For Treatment Of Mantle Cell Lymphoma And Chronic Lymphocytic Leukemia

June 30 (Reuters) - Oncternal Therapeutics Inc:

* ONCTERNAL THERAPEUTICS ANNOUNCES ORPHAN DRUG DESIGNATIONS OF CIRMTUZUMAB ROR1 ANTIBODY FOR TREATMENT OF MANTLE CELL LYMPHOMA AND FOR TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below